CFO
BIO icon

CVA Family Office’s Bio-Rad Laboratories Class A BIO Stock Holding History

CVA Family Office’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.98K Buy
34
+1
+3% +$284 ﹤0.01% 1020
2026
Q1 		$9.2K Buy
33
+29
+725% +$8.35K ﹤0.01% 1023
2025
Q4 		$1.21K Hold
4
– – ﹤0.01% 1073
2025
Q3 		$1.12K Buy
+4
New +$1.09K ﹤0.01% 1113
2025
Q2 		– Sell
-2
Closed -$487 – 1310
2025
Q1 		$487 Sell
2
-67
-97% -$20.2K ﹤0.01% 1282
2024
Q4 		$22.7K Hold
69
– – ﹤0.01% 654
2024
Q3 		$23.1K Buy
69
+2
+3% +$635 ﹤0.01% 631
2024
Q2 		$18.3K Buy
+67
New +$19.5K ﹤0.01% 656
2022
Q3 		– Sell
-15
Closed -$7K – 876
2022
Q2 		$7K Buy
15
+5
+50% +$2.6K ﹤0.01% 694
2022
Q1 		$6K Buy
10
+5
+100% +$3.01K ﹤0.01% 739
2021
Q4 		$4K Buy
+5
New +$3.74K ﹤0.01% 765
2021
Q3 		– Sell
-5
Closed -$3K – 421
2021
Q2 		$3K Sell
5
-15
-75% -$9.13K ﹤0.01% 821
2021
Q1 		$11K Buy
+20
New +$11.8K ﹤0.01% 506

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CVA Family Office's BIO Position: Q2 2026 in Review

CVA Family Office increased its Bio-Rad Laboratories Class A (BIO) stake by 3% in Q2 2026, buying an estimated $284 and bringing the position to 34 shares worth $9.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1020.

CVA Family Office first reported a position in BIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $23.1K in Q3 2024. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • CVA Family Office held 34 shares of Bio-Rad Laboratories Class A worth $9.98K as of Q2 2026.
  • CVA Family Office bought 1 Bio-Rad Laboratories Class A share in Q2 2026, an estimated $284.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1020 holding.
  • CVA Family Office first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and has held it in 13 quarters since.
  • CVA Family Office's Bio-Rad Laboratories Class A position peaked at $23.1K in Q3 2024.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.